| 1/5/2023 |
Lumen Bioscience Details 2022 Company and Facilities Growth, New Funding, and Clinical Pipeline Progress |
| 1/4/2023 |
Lumen Bioscience Receives Broad Funding Support for Advancement of Antibiotic Alternative for Preventing Traveler’s Diarrhea |
| 12/23/2022 |
Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections |
| 12/20/2022 |
BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study |
| 10/4/2022 |
Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria |
| 4/19/2022 |
KYORIN and Lumen Bioscience Reach Collaboration Research Agreement |
| 4/15/2022 |
Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection |
| 3/21/2022 |
Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins |
| 12/22/2021 |
Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection |
| 11/3/2021 |
Lumen Bioscience Partners with Leading Animal Health Company to Develop Oral Biologic Drugs and Reduce Antibiotic Use on Farms |
| 10/5/2021 |
Lumen Bioscience Awarded Federal Funding to Advance Covid-19 Antibody Cocktail through Phase 2 Clinical Evaluation |
| 8/31/2021 |
Lumen Bioscience Launches Phase 1 Trial of Oral Biologic Drug for Preventing C. difficile Infection Recurrence |
